Lexicon Pharmaceuticals, Inc. (LXRX) — Analysis Summary
Lexicon Pharmaceuticals, Inc. (LXRX) has a market cap of $963.91M with year-over-year revenue growth of +729.9%. Net margin stands at -101.1%. The stock trades at a P/E ratio of -36.9.
Key Takeaways
- Revenue changed +729.9% year-over-year
- Net margin of -101.1%
- P/E ratio of -36.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LXRX posted revenue growth of +729.9% and trades at a P/E of -36.9.
Lexicon Pharmaceuticals, Inc. (LXRX)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -34.8% — material operating losses
Net margin at -37.5% — significant losses
The latest filing shows negative free cash flow.
Gross margin at 99.5% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
81
Headquarters
THE WOODLANDS, TX
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.